Global Infectious Disease Therapeutics Market Assessment, By Mode of Treatment [Vaccines, Drugs], By Infection Type [Viral Infection, Bacterial Infection, Fungal Infection, Parasitic Infection, Others], By Route of Administration [Oral, Parenteral, Others], By Diagnostic Technique [Immunodiagnostics, Polymerase Chain Reaction, Clinical Microbiology, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing, Next Generation Sequencing, DNA Microarray, Others], By End-user [Hospitals, Diagnostic Centres, Retail Pharmacy, Others], By Region, Opportunities and Forecast, 2017-2031F

Global infectious disease therapeutics market is expected to grow due to several factors, including the increasing prevalence of infectious diseases, a rise in research and development activities, and increasing investment for healthcare infrastructure.

Home>Industry Reports>Global Infectious Disease Therapeutics Market Assessment, Opportunities and Forecast, 2017-2031F

Global infectious disease therapeutics market is projected to witness a CAGR of 5.76% during the forecast period 2024-2031, growing from USD 108.09 billion in 2023 to USD 169.15 billion in 2031. Infectious diseases have a significant impact on the global healthcare market, leading to economic, social, and health-related consequences. Tuberculosis accounted for the second highest deaths from infectious disease in 2022 after COVID-19. COVID-19, tuberculosis, HIV/AIDS, and malaria accounted for 1.24 million, 1.13 million, 0.63 million, and 0.62 million deaths respectively.  The global healthcare industry is under significant pressure due to infectious diseases, which are caused by various infectious agents such as viruses, viroids, and bacteria. Although advanced diagnosis and treatment options, as well as improvements in hygiene, vaccination, and antimicrobial therapy, have reduced the number of deaths caused by infectious diseases, the rise and re-occurrence of infectious diseases continue to affect global health outcome. The infectious disease therapeutics market is expected to grow significantly over the forecast period due to rising infectious disease occurrences, increased awareness about early infectious disease diagnosis, and increased research and funding activities by various private and government organizations.

For instance, WHO launched a global network to detect and prevent infectious disease threats in 2023. Not only does this initiative provide a platform to connect countries and regions, but it also improves the system for analyzing and collecting samples from around the globe, which will help and improve the public healthcare sector in decision-making and welfare.

Increasing Prevalence and Mortality Rate of Infectious Diseases

The increasing prevalence of infectious diseases is expected to drive the sales of infectious disease therapeutics in developing nations. Furthermore, significant investments in health research and life sciences in emerging countries are facilitating the adoption of advanced technologies, thereby promoting the diagnosis and treatment of infectious diseases. Morbidity and mortality are mainly caused due to infectious diseases. Such diseases are the cause of more than 33% or 52 million annual deaths, globally. Nearly half of the global population is at risk of recurring infectious diseases.

Countries, such as India, South Korea, Brazil, and Mexico, have a high burden of infectious diseases like Hepatitis, HAI, HIV, and influenza. As a result, medical device companies are increasing investments and manufacturing capacities in these countries to meet the demand for diagnostic devices and instruments over the forecast period.

Viral Therapeutics are Dominating the Market

In 2022, viral therapeutics held the second-largest market share in the infectious disease therapeutics sector. The significant share held by this segment is attributed to the growing prevalence of viral diseases like hepatitis and HIV, the increasing number of clinical trials for new drug launches, and initiatives aimed at enhancing drug adoption. Hepatitis and human papillomavirus patients are increasing at a rapid rate globally. Due to the rapid increase in the prevalence and incidence of infectious diseases, medical device manufacturers are prioritizing innovation and manufacturing capacities.

The World Health Organization's (WHO) Global Health Sector Strategy on viral hepatitis aims to test and treat a large proportion of individuals with HBV and HCV by 2030. In January 2023, the Serum Institute of India launched 'CERVAVAC,' the first Quadrivalent Human Papillomavirus vaccine made in India, in collaboration with DBT, BIRAC, and the Bill and Melinda Gates Foundation. This vaccine is India’s first indigenously developed vaccine for the prevention of cervical cancer. This vaccine is affordable and cost effective and the government of India has taken initiatives to make it accessible for everyone in the country.

Government Initiatives

Governments around the globe have been actively engaged in fostering advancements within the infectious disease therapeutics market through various initiatives. These efforts aim to address emerging health challenges and ensure preparedness for infectious outbreaks. Governments often allocate substantial funding for research and development, supporting pharmaceutical companies and academic institutions with their objective of developing innovative therapeutics. Additionally, regulatory bodies play a crucial role in streamlining the approval process to expedite the availability of new treatments. For instance, in India, the Infectious Disease Biology Program aims to provide solutions to infectious diseases of global concern such as HIV/AIDS, tuberculosis, and vector borne diseases, along with emerging or re-emerging threats like influenza, Japanese Encephalitis, and antibiotic-resistant microbes in terms of therapeutics, diagnostics, and preventive measures.  The Program supports R&D projects to achieve the Sustainable Development Goals Target to combat various water-borne diseases, communicable diseases, and hepatitis and end the epidemics of viral diseases like AIDS, TB, and malaria by the year 2030.

Dominance of Molecular Diagnostic Techniques, Especially PCR

Nucleic Acid amplification tests, PCR, are a few molecular diagnostic techniques that are going to be more popular in the coming frame of time. PCR is the most widely used nucleic acid amplification method for pathogen detection and has become an important tool in the early diagnosis of infectious diseases, bacterial infections, GI infections, and sexually transmitted diseases.

Thermo Fisher launched real-time PCR kits for the detection of infectious diseases in India in February 2023. The TaqPath PCR kits provide assurance and consistency for the creation and examination of diagnostic tests for infectious diseases. Genetic risk factor identification, therapy response monitoring, and disease screening are a few patient care practices that can be now carried out using the TaqPath PCR kits developed by Thermo Fisher.

North America Dominates Infectious Disease Therapeutics Market

North America is dominating the infectious diseases therapeutics market due to the increasing prevalence of infectious diseases, improving healthcare infrastructure, the presence of key market players, and rising awareness programs. Government initiatives and their effort towards providing the country with adequate infrastructure and facilities, such as trained professionals, high-end medical devices, and drugs, are creating lucrative market opportunities in the region. Other factors accelerating the market demand in North America includes the growing prevalence of such diseases, favorable reimbursement scenarios, the presence of numerous manufacturers in the U.S., and an increasing number of clinical trials for developing new treatment drugs and devices. According to the Centers for Disease Control and Prevention, in the United States., influenza and pneumonia caused 41,917 deaths in 2022.

Future Market Scenario (2024 – 2031F)

The future market scenario for treatments for infectious diseases is expected to be dynamic, driven by continued technological development and a greater emphasis on preventive measures. More individualized and efficient treatments are expected by the ongoing development of precision medicine, which is made possible by advancements in genomics and personalized therapies. Novel treatments for infectious diseases are being made possible by developments in immunotherapy and antiviral drugs, which are changing the market landscape. The COVID-19 pandemic has expedited the development, production, and distribution of vaccines, enabling a more responsive approach to newly emerging infectious diseases.

Report Scope

“Infectious Disease Therapeutics Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global infectious disease therapeutics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Report Attribute

Details

Base Year of the Analysis

2023

Historical Period

2017-2022

Forecast Period

2024-2031

Projected Growth Rate

CAGR of 5.76% between 2024 and 2031

Revenue Forecast in 2031

USD 169.15 billion

Segments Covered

Mode of Treatment, Infection Type, Route of Administration, Diagnostic Technique, End-user

Regions Covered

North America, Europe, South America, Asia-Pacific, Middle East and Africa

Key Companies Profile

·         AbbVie Inc., Boehringer Ingelheim GmbH, F Hoffmann-La Roche, Ltd, Bayer AG, GlaxoSmithKline plc., Pfizer Inc., Janssen Pharmaceutical (Johnson & Johnson), Merck & Co., Inc., Novartis AG, Moderna Inc., Eli Lilly & Co, Novo Nordisk, Applied Molecular Genetics Inc.

Customization Scope

15% free report customization with purchase

Pricing and Purchase Options

Avail the customized purchase options to fulfill your precise research needs

Delivery Format

PDF and Excel through email (subject to the license purchased)

In this report, the global infectious disease therapeutics market has been segmented into the following categories: 

·         By Mode of Treatment

o   Vaccines

o   Drugs

·         By Infection Type

o   Viral Infection

o   Bacterial Infection

o   Fungal Infection

o   Parasitic Infection

o   Others

·         By Route of Administration

o   Oral

o   Parenteral

§  Subcutaneous

§  Intravenous

§  Intradermal

§  Intramuscular

o   Others

·         By Diagnostic Technique

o   Immunodiagnostics

o   Polymerase Chain Reaction

o   Clinical Microbiology

o   Isothermal Nucleic Acid Amplification Technology

o   DNA Sequencing

o   Next Generation Sequencing

o   DNA Microarray

o   Others

·         By End-user

o   Hospitals

o   Diagnostic Centres

o   Retail Pharmacies

o   Others

·         By Region

o   North America

o   Europe

o   South America

o   Asia-Pacific

o   Middle East and Africa

Key Players Landscape and Outlook

The global market for infectious disease therapeutics is fiercely competitive and somewhat fragmented. To stay ahead, major industry players continuously implement various growth strategies such as innovations, mergers, acquisitions, collaborations, and partnerships. Additionally, they focus on research and development to provide the most effective and economical solutions. Most prominent players of this market, such as Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim GmbH, Bayer AG, Janssen Pharmaceutical, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc., are the ones mostly bringing new innovations and robust technology in the market.

In January 2023, Thermo Fisher Scientific Inc. (US) introduced the CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit. This kit is designed to detect genomic mutations in HIV-1 viral ribonucleic acid extracted from plasma or dried blood spots, specifically analyzing mutations in the protease, reverse transcriptase, and integrase regions of the pol gene.

Roche introduced the Elecsys HCV Duo in July 2022. This immunoassay enables the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. 

May & Baker Nigeria Plc launched Artelum Combo, a new drug to combat malaria parasites across Nigeria in March 2022. The medicine is a unique combination of Arthemeter Lumefantrine and Paracetamol, providing complete malaria therapy in a single package.

Key Players Operating in the Global Infectious Disease Therapeutics Market are:

·         AbbVie Inc.

·         Boehringer Ingelheim GmbH

·         F Hoffmann-La Roche, Ltd

·         Bayer AG

·         GlaxoSmithKline plc.

·         Pfizer Inc.

·         Janssen Pharmaceutical (Johnson & Johnson)

·         Merck & Co., Inc.

·         Novartis AG

·         Moderna, Inc.

·         Eli Lilly & Co

·         Novo Nordisk, Inc.

·         Applied Molecular Genetics Inc.

Markets and Data’s reports answer the following questions:

·         What is the current and future market size of the product/service in question globally or specific to different countries?

·         How are the markets divided into different product/service segments and the market size and growth of each segment?

·         What is the market potential of different product segments and their investment case?

·         How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

·         What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for the global infectious disease therapeutics market, you may approach our team at info@marketsandata.com

Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Executive Summary

4.       Global Infectious Disease Therapeutics Market Outlook, 2017-2031F

4.1. Market Size & Forecast

4.1.1.       Value

4.1.2.       Volume

4.2. By Mode of Treatment  

4.2.1.       Vaccines

4.2.2.       Drugs

4.3. By Infection Type

4.3.1.       Viral Infection

4.3.2.       Bacterial Infection

4.3.3.       Fungal Infection

4.3.4.       Parasitic Infection

4.3.5.       Others

4.4. By Route of Administration

4.4.1.       Oral

4.4.2.       Parenteral

4.4.2.1.  Subcutaneous

4.4.2.2.  Intravenous

4.4.2.3.  Intradermal

4.4.2.4.  Intramuscular

4.4.3.       Others

4.5. By Diagnostic Technique

4.5.1.       Immunodiagnostics

4.5.2.       Polymerase Chain Reaction

4.5.3.       Clinical Microbiology

4.5.4.       Isothermal Nucleic Acid Amplification Technology

4.5.5.       DNA Sequencing

4.5.6.       Next Generation Sequencing

4.5.7.       DNA Microarray

4.5.8.       Others

4.6. By End-user

4.6.1.       Hospitals

4.6.2.       Diagnostic Centres

4.6.3.       Retail Pharmacies

4.6.4.       Others

4.7. By Region

4.7.1.       North America

4.7.2.       Europe

4.7.3.       South America

4.7.4.       Asia-Pacific

4.7.5.       Middle East and Africa

4.8. By Company Market Share (%), 2023

5.       Global Infectious Disease Therapeutics Market Outlook, By Region, 2017-2031F

5.1. North America*

5.1.1.       Market Size & Forecast

5.1.1.1.  Value

5.1.1.2.  Volume

5.1.2.       By Mode of Treatment  

5.1.2.1.  Vaccines

5.1.2.2.  Drugs

5.1.3.       By Infection Type

5.1.3.1.  Viral Infection

5.1.3.2.  Bacterial Infection

5.1.3.3.  Fungal Infection

5.1.3.4.  Parasitic Infection

5.1.3.5.  Others

5.1.4.       By Route of Administration

5.1.4.1.1.        Oral

5.1.4.1.2.        Parenteral

5.1.4.1.2.1.   Subcutaneous

5.1.4.1.2.2.   Intravenous

5.1.4.1.2.3.   Intradermal

5.1.4.1.2.4.   Intramuscular

5.1.4.1.3.        Others

5.1.5.       By Diagnostic Technique

5.1.5.1.  Immunodiagnostics

5.1.5.2.  Polymerase Chain Reaction

5.1.5.3.  Clinical Microbiology

5.1.5.4.  Isothermal Nucleic Acid Amplification Technology

5.1.5.5.  DNA Sequencing

5.1.5.6.  Next Generation Sequencing

5.1.5.7.  DNA Microarray

5.1.5.8.  Others

5.1.6.       By End-user

5.1.6.1.  Hospitals

5.1.6.2.  Diagnostic Centres

5.1.6.3.  Retail Pharmacies

5.1.6.4.  Others

5.1.7.        United States*

5.1.7.1.  Market Size & Forecast

5.1.7.1.1.        By Value

5.1.7.1.2.        By Volume

5.1.7.2.  By Mode of Treatment  

5.1.7.2.1.        Vaccines

5.1.7.2.2.        Drugs

5.1.7.3.  By Infection Type

5.1.7.3.1.        Viral Infection

5.1.7.3.2.        Bacterial Infection

5.1.7.3.3.        Fungal Infection

5.1.7.3.4.        Parasitic Infection

5.1.7.3.5.        Others

5.1.7.4.  By Route of Administration

5.1.7.4.1.1.   Oral

5.1.7.4.1.2.   Parenteral

5.1.7.4.1.2.1.         Subcutaneous

5.1.7.4.1.2.2.         Intravenous

5.1.7.4.1.2.3.         Intradermal

5.1.7.4.1.2.4.         Intramuscular

5.1.7.4.1.3.   Others

5.1.7.5.  By Diagnostic Technique

5.1.7.5.1.        Immunodiagnostics

5.1.7.5.2.        Polymerase Chain Reaction

5.1.7.5.3.        Clinical Microbiology

5.1.7.5.4.        Isothermal Nucleic Acid Amplification Technology

5.1.7.5.5.        DNA Sequencing

5.1.7.5.6.        Next Generation Sequencing

5.1.7.5.7.        DNA Microarray

5.1.7.5.8.        Others

5.1.7.6.  By End-user

5.1.7.6.1.        Hospitals

5.1.7.6.2.        Diagnostic Centres

5.1.7.6.3.        Retail Pharmacies

5.1.7.6.4.        Others

5.1.8.       Canada

5.1.9.       Mexico

*All segments will be provided for all regions and countries covered

5.2. Europe

5.2.1.       Germany

5.2.2.       France

5.2.3.       Italy

5.2.4.       United Kingdom

5.2.5.       Russia

5.2.6.       Spain

5.2.7.       Others

5.3. South America

5.3.1.       Brazil

5.3.2.       Argentina

5.4. Asia-Pacific

5.4.1.       India

5.4.2.       China

5.4.3.       Japan

5.4.4.       Australia

5.4.5.       South Korea

5.4.6.       Others

5.5. Middle East & Africa

5.5.1.       Saudi Arabia

5.5.2.       UAE

5.5.3.       South Africa

6.       Market Mapping, 2023

6.1. By Mode of Treatment

6.2. By Infection Type

6.3. By Route of Administration

6.4. By Diagnostic Technique

6.5. By End-user

6.6. By Region

7.       Macro Environment and Industry Structure

7.1. Supply Demand Analysis

7.2. Import Export Analysis

7.3. Value Chain Analysis

7.4. PESTEL Analysis

7.4.1.       Political Factors

7.4.2.       Economic System

7.4.3.       Social Implications

7.4.4.       Technological Advancements

7.4.5.       Environmental Impacts

7.4.6.       Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5. Porter’s Five Forces Analysis

7.5.1.       Supplier Power

7.5.2.       Buyer Power

7.5.3.       Substitution Threat

7.5.4.       Threat from New Entrant

7.5.5.       Competitive Rivalry

8.       Market Dynamics

8.1. Growth Drivers

8.2. Growth Inhibitors (Challenges and Restraints)

9.       Regulatory Framework and Innovation

9.1. Clinical Trials

9.2. Patent Landscape

9.3. Regulatory Approvals

9.4. Innovations/Emerging Technologies

10.   Key Players Landscape

10.1.                   Competition Matrix of Top Five Market Leaders

10.2.                   Market Revenue Analysis of Top Five Market Leaders (in %, 2023)

10.3.                   Mergers and Acquisitions/Joint Ventures (If Applicable)

10.4.                   SWOT Analysis (For Five Market Players)

10.5.                   Patent Analysis (If Applicable)

11.   Pricing Analysis

12.   Case Studies

13.   Key Players Outlook

13.1.                   AbbVie Inc.

13.1.1.    Company Details

13.1.2.    Key Management Personnel

13.1.3.    Products & Services

13.1.4.    Financials (As reported)

13.1.5.    Key Market Focus & Geographical Presence

13.1.6.    Recent Developments

13.2.                   Boehringer Ingelheim GmbH

13.3.                   F Hoffmann-La Roche, Ltd

13.4.                   Bayer AG

13.5.                   GlaxoSmithKline plc.

13.6.                   Pfizer Inc.

13.7.                   Janssen Pharmaceutical (Johnson & Johnson)

13.8.                   Merck & Co., Inc.

13.9.                   Novartis AG

13.10.                Moderna, Inc.

13.11.                Eli Lilly & Co

13.12.                Novo Nordisk, Inc.

13.13.                Applied Molecular Genetics Inc.

 

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14.   Strategic Recommendations

15.   About Us & Disclaimer

List of Figures:

Figure 1. Global Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 2. Global Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 3. Global Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 4. Global Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 5. Global Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 6. Global Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 7. Global Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 8. Global Infectious Disease Therapeutics Market Share (%), By Region, 2017-2031F

Figure 9. North America Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 10. North America Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 11. North America Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 12. North America Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 13. North America Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 14. North America Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 15. North America Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 16. North America Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F

Figure 17. United States Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 18. United States Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 19. United States Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 20. United States Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 21. United States Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 22. United States Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 23. United States Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 24. Canada Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 25. Canada Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 26. Canada Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 27. Canada Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 28. Canada Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 29. Canada Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 30. Canada Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 31. Mexico Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 32. Mexico Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 33. Mexico Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 34. Mexico Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 35. Mexico Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 36. Mexico Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 37. Mexico Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 38. Europe Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 39. Europe Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 40. Europe Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 41. Europe Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 42. Europe Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 43. Europe Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 44. Europe Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 45. Europe Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F

Figure 46. Germany Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 47. Germany Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 48. Germany Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 49. Germany Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 50. Germany Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 51. Germany Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 52. Germany Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 53. France Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 54. France Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 55. France Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 56. France Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 57. France Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 58. France Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 59. France Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 60. Italy Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 61. Italy Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 62. Italy Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 63. Italy Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 64. Italy Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 65. Italy Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 66. Italy Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 67. United Kingdom Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 68. United Kingdom Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 69. United Kingdom Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 70. United Kingdom Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 71. United Kingdom Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 72. United Kingdom Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 73. United Kingdom Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 74. Russia Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 75. Russia Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 76. Russia Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 77. Russia Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 78. Russia Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 79. Russia Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 80. Russia Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 81. Netherlands Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 82. Netherlands Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 83. Netherlands Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 84. Netherlands Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 85. Netherlands Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 86. Netherlands Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 87. Netherlands Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 88. Spain Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 89. Spain Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 90. Spain Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 91. Spain Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 92. Spain Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 93. Spain Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 94. Spain Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 95. Turkey Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 96. Turkey Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 97. Turkey Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 98. Turkey Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 99. Turkey Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 100. Turkey Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 101. Turkey Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 102. Poland Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 103. Poland Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 104. Poland Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 105. Poland Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 106. Poland Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 107. Poland Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 108. Poland Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 109. South America Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 110. South America Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 111. South America Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 112. South America Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 113. South America Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 114. South America Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 115. South America Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 116. South America Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F

Figure 117. Brazil Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 118. Brazil Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 119. Brazil Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 120. Brazil Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 121. Brazil Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 122. Brazil Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 123. Brazil Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 124. Argentina Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 125. Argentina Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 126. Argentina Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 127. Argentina Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 128. Argentina Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 129. Argentina Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 130. Argentina Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 131. Asia-Pacific Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 132. Asia-Pacific Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 133. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 134. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 135. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 136. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 137. Asia- Pacific Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 138. Asia-Pacific Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F

Figure 139. India Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 140. India Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 141. India Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 142. India Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 143. India Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 144. India Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 145. India Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 146. China Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 147. China Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 148. China Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 149. China Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 150. China Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 151. China Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 152. China Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 153. Japan Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 154. Japan Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 155. Japan Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 156. Japan Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 157. Japan Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 158. Japan Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 159. Japan Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 160. Australia Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 161. Australia Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 162. Australia Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 163. Australia Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 164. Australia Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 165. Australia Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 166. Australia Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 167. Vietnam Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 168. Vietnam Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 169. Vietnam Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 170. Vietnam Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 171. Vietnam Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 172. Vietnam Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 173. Vietnam Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 174. South Korea Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 175. South Korea Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 176. South Korea Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 177. South Korea Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 178. South Korea Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 179. South Korea Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 180. South Korea Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 181. Indonesia Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 182. Indonesia Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 183. Indonesia Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 184. Indonesia Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 185. Indonesia Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 186. Indonesia Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 187. Indonesia Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 188. Philippines Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 189. Philippines Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 190. Philippines Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 191. Philippines Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 192. Philippines Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 193. Philippines Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 194. Philippines Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 195. Middle East & Africa Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 196. Middle East & Africa Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 197. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 198. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 199. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 200. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 201. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 202. Middle East & Africa Infectious Disease Therapeutics Market Share (%), By Country, 2017-2031F

Figure 203. Saudi Arabia Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 204. Saudi Arabia Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 205. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 206. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 207. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 208. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 209. Saudi Arabia Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 210. UAE Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 211. UAE Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 212. UAE Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 213. UAE Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 214. UAE Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 215. UAE Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 216. UAE Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 217. South Africa Infectious Disease Therapeutics Market, By Value, In USD Billion, 2017-2031F

Figure 218. South Africa Infectious Disease Therapeutics Market, By Volume, In Million Units, 2017-2031F

Figure 219. South Africa Infectious Disease Therapeutics Market Share (%), By Mode of Treatment, 2017-2031F

Figure 220. South Africa Infectious Disease Therapeutics Market Share (%), By Infection Type, 2017-2031F

Figure 221. South Africa Infectious Disease Therapeutics Market Share (%), By Route of Administration, 2017-2031F

Figure 222. South Africa Infectious Disease Therapeutics Market Share (%), By Diagnostic Technique, 2017-2031F

Figure 223. South Africa Infectious Disease Therapeutics Market Share (%), By End-user, 2017-2031F

Figure 224. By Mode of Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 225. By Infection Type Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 226. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 227. By Diagnostic Technique Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

List of Tables

Table 1. Pricing Analysis of Products from Key Players

Table 2. Competition Matrix of Top 5 Market Leaders

Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)

Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

What are the major drivers influencing the growth of the global infectious disease therapeutics market?

arrowup
Heart

Global E-bike Battery Market Assessment, Opportunities and Forecast, 2017-2031F

The increased popularity of e-bikes along with the increasing adoption of compact vehicles for adventure sport and exploration is propelling the market expansion. ....Read More

Published on

April 2024

4,500

Heart

Global Chloroxylenol Market Assessment, Opportunities and Forecast, 2017-2031F

Global chloroxylenol market is expected to experience significant growth over the forecast period owing to the antimicrobial properties of chloroxylenol, increasing emphasis on maintaining skin health and personal hygiene, and growing threat of surgi....Read More

Published on

April 2024

4,500

Heart

Global Gabapentin Market Assessment, Opportunities and Forecast, 2017-2031F

Global gabapentin market will experience significant growth over the forecast period due to the rising investments in product innovation activities by the pharmaceutical companies and increasing incidences of seizures.....Read More

Published on

April 2024

4,500

Heart

Global Magnesium Citrate Market Assessment, Opportunities and Forecast, 2017-2031F

Global magnesium citrate market will witness significant growth over the forecast period owing to rapid expansion of the pharmaceutical sector and increasing research and development activities.....Read More

Published on

April 2024

4,500

Purchase Options

USD ($)

arrowdown

i

3,000

i

4,500

i

5,700

i

8,200

Tired of Searching?

Looking for Customization?

Some other doubt?

Need insights from a cohort?

REACH US

    icon_Five
    17, Okhla Industrial Estate Phase 3 Rd, Okhla Phase III, Okhla Industrial Estate, New Delhi, Delhi 110020
    call_Two
    +91 11 42343567
    icon_Six
    info@marketsandata.com
icon_Seven
5741 Cleveland street, Suite 120, VA beach, VA, USA 23462
call_Three
+1 (757) 343-3258
icon_Eight
190 Middle Road, # 14-10 Fortune Centre, Singapore -188979